Christopher Barys Named U.S. President, Chief Commercial Officer at Radiaction Medical

Radiaction Medical Ltd. has appointed Christopher Barys as its U.S. president and chief commercial officer to lead U.S. commercialization efforts and operations.
 
“In the midst of a rapidly changing healthcare environment, protection for interventional staff has remained stagnant, to the detriment of those healthcare workers who are in the direct line of harm from scatter radiation,” Barys said. “Innovative, clinically supported solutions are needed now more than ever, and Radiaction is answering the call. I am proud to play a key role in its mission to bring forth a new model of advanced radiation protection to the healthcare providers that need it most.”
 
Barys joined Radiaction’s Board of Directors in 2023 and will remain on the board as he steps into his new role. Last summer, the company raised $12.6 million in Series C2 funding led by U.S. private equity fund InnovaHealth Partners with participation from additional co-investors. The company is currently focused on expanding its footprint in the United States, adding new sites to its user base, and growing its clinical publication pipeline to support the technology’s performance with clinical data.

Barys most recently served as president/CEO of On Target Laboratories for nearly four years, according to his LinkedIn profile. Prior to that, he was senior vice president and business leader for Image Guided Therapy – Devices at Philips Health Systems North America. Barys worked for Medtronic for two years as vice president and general manager, Interventional Lung Solutions. From May 2011 to January 2014, Barys was general manager of Kimberly-Clark’s Global Surgical Plan; before that, he was a consultant for US HIFU, a developer, manufacturer and distributor of high-intensity focused ultrasound therapy for prostate cancer treatment. Barys was executive vice president and chief operating officer of FlowCardia Inc. between November 2007 and July 2009. He also held various sales positions at Edwards Lifesciences, Cordis Cardiology, and Schneider Worldwide. 
 
“When we met Chris, I knew he had the right experience and vision to steer Radiaction through our next stage of growth. With his extensive track record of market development within the interventional space, Chris is a tremendous asset to the strategic composition of our leadership team. I am excited to work alongside him in bringing our radiation protection solution to interventional teams across the country,” Radiaction CEO Jonathan Yifat stated.
 
Radiaction Medical Ltd., is revolutionizing radiation protection for interventional medical teams, focused on specialties that endure the highest exposure rates and serious health risks. In a complete departure from current solutions that shield or clothe users to block radiation, the company created Radiaction, a plug-and-play addition to C-arm systems that dynamically and proactively blocks up to 97% of scatter radiation at the source, offering head-to-toe protection for everyone in the room. Radiaction has received CE Marking and FDA clearance and is currently being marketed in North America. Based in Tel Aviv, Israel, Radiaction Medical was founded by Amir Belson, M.D., with lead investor InnovaHealth Partners LP.